It's still the beginning, and the beginning is when you have to be tough.

The jewels are the vaccines business and blood testing. There's nothing about Chiron that makes you say 'wow, we need to buy this for the pipeline.' The portfolio is rather lackluster compared to other biotechnology companies.

It is a good marketing tool that the FDA has approved it, so I am quite sure they will make some inroads in the U.S. That is for sure.